Stellantis’ Post

$ME1 - Melodiol Global Health has accumulated about 1.39 M in cash with (17.31 M) of positive cash flow from operations.. 20 for 1 Split on the 25th of January can force Melodiol Global to revert back: About 69.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.15. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Melodiol Global Health recorded a loss per share of 0.6. The entity had not issued any dividends in recent years. The firm had 0.05:1 split on the 25th of January 2024. https://lnkd.in/g9W8Jaqu #stocks #stocktwits #thematic_portfolio

When Ligentia needed to enhance its supply chain portal, Windward demonstrated impressive results: 📈 39% increase in accuracy over carrier ETA ⏱️ 70% improvement in 24-hour accuracy 🔮 109% better predictions 10 days out from arrival Here’s how we empowered data-driven decision-making for Ligentia 👉 https://hubs.la/Q02DntjQ0 #SupplyChain #SupplyChainManagement #MaritimeTechnology

As part of our Partner First Strategy, a dedicated delivery team has invested significant effort to curate an extensive knowledge repository for PIM/MDM. Here's a sneak peek into the offerings by this focused delivery team for empowering Partner resources and it will be unveiled at Syndigo Partner Kickoff in Nice, France led by Pravin Patil Knowledge Repository Arsenal: 🥇 80+ articles spanning a wide spectrum. 🥇51 ready-to-use presentations for enhanced understanding & workshops 🥇15 templates crafted for seamless implementation and documentation, scoping & estimations 🥇22 knowledge articles for a deep dive. 🥇 In-depth insights into Match & Merge functionalities, marketplace apps 🥇 Guidelines on best practices and troubleshooting documents Accelerators: 🥇Dynamic ready-to-use presentations for discovery/design workshops. 🥇Configurations for PIM/MDM/GDSN accelerators. 🥇Use case master cutting across diverse domains Register now: https://lnkd.in/gXszhdqP  for excellence in #mdm #pim #customer360 #GDSN implementation success. Carlos Dufour Ratish Nair

Summit Therapeutic (SMMT US) Ranked Positive On March 28th, 2024 Ankur Dhingra (CFO since 2022) purchased $375,000 of stock on the 26th of March at $3.75, increasing his stake by 39%. This is much his largest purchase or subscription and also much the highest price he has paid. His only previous clean purchase was for $44,000 of stock at $2.17 and it’s very notable to see him now buying in size at a higher price.  Mahkam Zanganeh (Co-CEO since 2022, joined 2020) purchased $411,000 of stock on the 26th of March. Whilst modest relative to her 3.6% stake and previous subscriptions, this is her first proper-sized clean purchase.  We are ranking the stock +1. Learn more: https://lnkd.in/ejzziraH #USstockmarket #smartinsider #insidertrading #equities #alternativedata #trading #investing #investment #insiderdeals #insidertransaction #stockmarket #stockmarkets #investmentmanagement #portfoliomanagement #portfoliomanager #investmentstrategy #altdata

Excited about the progress we have made at Secureworks. Q4: *ARR: $285 million *Profitable: Adjusted EBITDA $3.8 million *41% YoY Taegis revenue growth *Taegis average revenue per customer is leading peers by more than 60% *Cloud cost per endpoint down nearly 20% over the last two years *Q4 non-GAAP Taegis gross margin 73.1% *Strong Balance Sheet: $69 million in cash, no debt and an undrawn $50 million credit facility *SecOps triage productivity improved by over 100% over the last year *Received the Frost & Sullivan Competitive Strategy Leadership Award in the Global XDR Industry. Read our full release: https://scwx.us/vO

Buy & Sell Signals How To Trade Globus Medical Inc. Class A ($GMED): Stock Traders Daily has produced this trading report using a proprietary method.  This methodology [...] Look at the Charts

We're embarking on a strategic review to ensure our sustainable development and maximize value for our shareholders. This entails examining both organic and non-organic growth opportunities, optimizing our balance sheet structure, and determining the most suitable trading platform for our shares on a regulated market. As part of this process, we're considering the possibility of listing our shares on an international stock exchange, including the London Stock Exchange, within the next 9-12 months. This move aligns with our increasingly diversified and international geographic presence. #MYTILINEOS #SustainableGrowth #InternationalExpansion #LondonStockExchange

#MYTILINEOS launches a strategic review to ensure its sustainable development and value creation for its shareholders. This comprehensive review includes the examination of organic and non-organic growth opportunities, optimization of the balance sheet structure and the most appropriate structure for trading the shares on a regulated market. In this context, #MYTILINEOS is considering the possibility of listing its shares on an international stock exchange, including the London Stock Exchange, within the next 12-18 months, taking into account its increasingly diversified and international geographic presence.

ICYMI below is a link to the video of the presentation I did on behalf of Immuron on Sharewise providing an update on continued Travelan® growth and progression of two therapeutics in Phase 2 and pre-IND filing for another. #ASX #IMC #nasdaq #IMRN #travel #guthealth

ICYMI below is a link to the video of the presentation our CEO, Steven Lydeamore made on Sharewise providing an update on continued Travelan® growth and progression of two therapeutics in Phase 2 and pre-IND filing for another. #ASX #IMC #nasdaq #IMRN #travel #guthealth